ImmunoGen, Inc. (IMGN) Short Interest Update

ImmunoGen, Inc. (NASDAQ:IMGN) saw a large growth in short interest in January. As of January 31st, there was short interest totalling 13,376,094 shares, a growth of 10.7% from the January 12th total of 12,085,660 shares. Currently, 10.3% of the company’s stock are short sold. Based on an average daily volume of 3,192,151 shares, the short-interest ratio is presently 4.2 days.

Hedge funds and other institutional investors have recently modified their holdings of the company. Arrowstreet Capital Limited Partnership purchased a new position in ImmunoGen during the 2nd quarter worth approximately $102,000. Intl Fcstone Inc. purchased a new position in ImmunoGen during the 2nd quarter worth approximately $115,000. Raymond James Financial Services Advisors Inc. purchased a new position in ImmunoGen during the 2nd quarter worth approximately $126,000. Virginia Retirement Systems ET AL purchased a new position in ImmunoGen during the 3rd quarter worth approximately $136,000. Finally, SG Americas Securities LLC grew its stake in ImmunoGen by 75.7% during the 4th quarter. SG Americas Securities LLC now owns 18,416 shares of the biotechnology company’s stock worth $118,000 after buying an additional 7,937 shares during the last quarter. 67.88% of the stock is currently owned by institutional investors and hedge funds.

Shares of ImmunoGen (IMGN) traded up $0.15 during midday trading on Friday, hitting $8.91. The stock had a trading volume of 3,692,143 shares, compared to its average volume of 3,245,576. The company has a quick ratio of 2.78, a current ratio of 2.81 and a debt-to-equity ratio of -0.03. ImmunoGen has a 1-year low of $2.31 and a 1-year high of $10.04. The firm has a market cap of $1,330.00, a price-to-earnings ratio of -6.59 and a beta of 2.50.

ImmunoGen (NASDAQ:IMGN) last issued its earnings results on Friday, February 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). The firm had revenue of $39.40 million during the quarter, compared to analyst estimates of $39.62 million. During the same quarter in the previous year, the business earned ($0.39) earnings per share. The business’s quarterly revenue was up 185.5% on a year-over-year basis. sell-side analysts forecast that ImmunoGen will post -0.97 earnings per share for the current year.

IMGN has been the topic of a number of analyst reports. Zacks Investment Research raised ImmunoGen from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a research report on Tuesday, October 31st. Jefferies Group reissued a “buy” rating and set a $9.00 target price on shares of ImmunoGen in a research report on Thursday, October 12th. BidaskClub raised ImmunoGen from a “hold” rating to a “buy” rating in a research report on Thursday, January 18th. Cantor Fitzgerald reissued a “hold” rating and set a $5.00 target price on shares of ImmunoGen in a research report on Friday, November 3rd. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $12.00 target price on shares of ImmunoGen in a research report on Thursday. Two research analysts have rated the stock with a sell rating, two have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $7.83.

COPYRIGHT VIOLATION NOTICE: “ImmunoGen, Inc. (IMGN) Short Interest Update” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/09/immunogen-inc-imgn-short-interest-update.html.

About ImmunoGen

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply